We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Final Guidance Includes Reporting Scenarios for Cell- and Tissue-Based Products
FDA Final Guidance Includes Reporting Scenarios for Cell- and Tissue-Based Products
The FDA finalized its 2015 guidance on reporting deviations for human cells, tissues and cellular and tissue-based products, also known as HCT/Ps, offering recommendations for complying with federal reporting requirements and listing the most frequent reports received by CBER.